Literature DB >> 29739948

A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms.

Yong Gao1,2,3, Hao Gao1,2,3, Guangfu Wang1,2,3, Lingdi Yin1,2,3, Wenbin Xu1,2,3, Yunpeng Peng1,2,3, Junli Wu1,2,3, Kuirong Jiang1,2,3, Yi Miao4,5,6.   

Abstract

Pancreatic neuroendocrine neoplasms (pNENs) are a group of clinically rare and heterogeneous diseases of the pancreas. However, the prognostic factors for this disease in patients still remain controversial. The purpose of our study is to evaluate the predictive roles of those prognostic factors for pNENs. All related articles published until Sep 17, 2017 were identified via PubMed, EMBASE, Web of Science, Ovid and the Cochrane Library. Studies that examined the prognostic factors of pNENs were enrolled. 17 articles (2822 patients) were finally included in this study. The pooled data suggested that patients with positive surgical resection margin and lymph node, advanced G stage and TMN stage, organ metastasis, vascular invasion and the necrosis of specimens had a decreased overall survival for pNENs. Similarly, patients with functional tumors might have a poor prognosis. However, age, gender, surgical type and size of tumor could not be regarded as prognostic factors for pNENs. Our analytic data demonstrated that surgical resection margin, G stage, TMN stage, lymph node, metastasis, vascular invasion and the necrosis could be prognostic factors for pNENs. Our study may assist doctors to screen patients with different prognosis more efficiently during follow-up and select appropriate treatment measures.

Entities:  

Mesh:

Year:  2018        PMID: 29739948      PMCID: PMC5940798          DOI: 10.1038/s41598-018-24072-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Pancreatic neuroendocrine neoplasms (pNENs), derived from different neuroendocrine cells, are a clinically rare and heterogeneous disease of the pancreas[1,2]. Since Seale Harris et al. the first time describing endogenous insulinoma in 1924, more and more subtypes of pNENs have been reported such as glucagonoma, gastrinoma, VIPoma, Somatostatinoma and CCK-oma[3]. While the percentage of PNENs in all pancreatic tumors is only 1% to 2%, the incidence has increased apparently in the past few years[4,5]. Meanwhile, the interest on pancreatic neuroendocrine neoplasms (pNENs) has grown[6]. However, we still lack understanding of this disease. The prognosis of pNENs in the population varies. As reported in some studies[7-10], a large number of factors including older age, large tumor size, positive resection margin, advanced G stage and TMN stage, vascular invasion, organ metastasis could indicate a poor prognosis of pNENs. In contrast, people with function tumors, low tumor marks might have a better outcome. Unfortunately, the results of these studies were controversial, and the sample size of them was relatively limited. Effective prognostic factors are in great need. Thus we performed this meta-analysis to further evaluate the predictive roles of these prognostic factors for pNENs.

Result

Study selection

The identification and selection process for this meta-analysis are illustrated in Fig. 1. A total of 2026 publications were identified in the initial literature search. Based on screening of titles or abstracts, 1455 records were excluded. 35 articles were left for the further full text assessment. According to the inclusion and exclusion criteria mentioned in materials and methods, 18 articles were excluded and 17 articles were finally included for this meta-analysis.
Figure 1

The identification and selection process for this meta-analysis.

The identification and selection process for this meta-analysis.

Study characteristics

The main characteristics of these included articles were shown in Table 1. A total of 17 studies with 2822 patients (range from 19–1483 per study) were assessed in this meta-analysis[11-27]. Studies included were published from 2007 to 2017. Study period ranged from 1964 to 2015. Among them, 11 studies studied the patients from Asian countries, including Japan (2), South Korea (1), and China (8); 7 studies investigated the patients from European countries and North American countries, including America (3), Germany (2), Spain (1) and Norway (1). All of studies were retrospective studies. Moreover, the results of study quality assessment were also listed in Table 1.
Table 1

Main characteristics of included articles.

AuthorYearCountryStudy periodSample sizeStudy typeQuality assessment
Tao Ming et al.2014China2007–201332retrospective7
Nils D. Arvold et al.2011USA1983–201046retrospective6
Marcus Bahra et al.2007Germany1989–200319retrospective6
Raziye Boyar Cetinkaya et al.2014Norway1982–2010114retrospective8
Cheng Yugang et al.2016China2003–2015100retrospective8
Javier A. Cienfuegos et al.2016Spain1993–201579retrospective7
Resit Demir et al.2011Germany1964–200682retrospective7
GaoChuntao et al.2010China1980–2003112retrospective8
GeWenhao et al.2017China2007–201353retrospective7
T. R. Halfdanarson et al.2008USA1973–20001483retrospective8
HanXu et al.2017China2004–2013104retrospective8
Satoshi Shiba et al.2016Japan1991–2010100retrospective8
Katsunobu Taki et al.2017Japan2001–201483retrospective7
Joyce Wong et al.2014USA1999–2012131retrospective8
Yang M. et al.2015China2002–2012125retrospective8
YangMin et al.2014China2000–201355retrospective6
ZhouBo et al.2017China2002–2013104retrospective8
Main characteristics of included articles.

Prognostic factors for pancreatic neuroendocrine neoplasms

clinical feature prognostic factors

3 clinical feature prognostic factors were analyzed in this study, including gender, age, and function. All pooled data about these factors were shown in Table 2.
Table 2

Pooled data about clinical feature prognostic factors.

FactorNumber of articlesOR95% CIPI2(%)
Gender41.650.64–4.270.367
Age41.031.00–1.050.0345
Function70.750.63–0.900.00237
Pooled data about clinical feature prognostic factors.

Gender

A total of 4 articles[13,17,18,21] assessed the effect of gender on the prognosis of pNENs. 3 of them[13,17,18] considered that there was no difference in prognosis between male and female patients and the pooled hazard ratio (HR) and 95% confidence interval (CI) supported this view. The rest one[21] showed that male patients might have a poor prognosis of pNENs (Table 2, Fig. 2A). According to the subgroup analysis, equal survival tendency to males and females was only observed in results obtained from studies with larger sample size, and performed in Asia area.
Figure 2

Forest plot of the association between pNENs and clinical feature and surgery prognostic factors. (A) The association between pNENs and gender. (B) The association between pNENs and age. (C) The association between pNENs and function. (D) The association between pNENs and surgical margin. (E) The association between pNENs and surgical type.

Forest plot of the association between pNENs and clinical feature and surgery prognostic factors. (A) The association between pNENs and gender. (B) The association between pNENs and age. (C) The association between pNENs and function. (D) The association between pNENs and surgical margin. (E) The association between pNENs and surgical type.

Age

1 of 4 articles[13] suggested that patients with older age had a worse outcome than the patient with younger age (Table 2, Fig. 2B). However, the combined data and all subgroup results all showed that there was no significant difference between young patients and old patients.

Function

Function was enrolled in 7 articles[11,13,14,16,18,22,27]. Although up to 5 of 7 articles[11,13,18,22,27] found no statistically significant difference in the prognosis of functional and nonfunctional tumors, the combined result reported that functional tumors could improve the prognosis of pNENs (Table 2, Fig. 2C), as well as the subgroup results based on the articles enrolled more than or equal to 80 patients or published in western countries. However, articles published in Asia agreed with the previous point.

Surgery related prognostic factors

2 surgery related prognostic factors were investigated in our study. All synthetic data about these factors were shown in Table 3.
Table 3

Synthetic data about surgery related prognostic factors.

FactorNumber of articlesOR95% CIPI2(%)
Surgical margin412.933.31–50.540.000271
Surgical type22.890.17–49.700.4780
Synthetic data about surgery related prognostic factors.

Surgical margin

1 of 4 article[12] showed that there was no significant difference between patients with positive and negative surgical resection margin (Table 3, Fig. 2D). However, the combined result and subgroup result based on articles more than 80 patients all revealed that negative surgical margin was another positive prognostic factor for pNENs.

Surgical type

Nils D. Arvold et al.[17] suggested that more extensive surgery was associated with decreased OS but the study[23] carried by Marcus Bahra et al. showed inconsistent trend (Table 3, Fig. 2E).

Pathology related prognostic factor

7 pathology related prognostic factors were assessed in our study. All combined data about these factors were shown in the Table 4.
Table 4

Combined data about pathology related prognostic factors.

FactorNumber of articlesOR95% CIPI2(%)
G stage65.432.46–11.99<0.00012
TMN stage48.562.00–36.710.0040
Lymph node62.961.25–7.030.0193
Vascular invasion31.931.14–3.280.0147
Organ metastasis44.52.65–7.62<0.000136
Tumor size51.021.00–1.040.0090
Necrosis23.581.86–6.890.00010
Combined data about pathology related prognostic factors.

G stage

2 of 6 studies[13,21] suggested that poor prognosis of pNENs was associated with advanced G stage, while 4 of 6 studies[12,20,26,27] had no statistical difference between people with high or low G stage. Our pooled data showed that patients with advanced G stage were prone to suffer from pNENs (Table 4, Fig. 3A). Meanwhile, subgroup analysis suggested that G stage is a negative prognostic factor for pNENs according to the pooled data from articles published in Asian and articles with more than or equal to 80 patients
Figure 3

Forest plot of the association between pNENs and pathology related prognostic factor. (A) The association between pNENs and G stage. (B) The association between pNENs and lymph node invasion. (C) The association between pNENs and vascular invasion. (D) The association between pNENs and metastasis.

Forest plot of the association between pNENs and pathology related prognostic factor. (A) The association between pNENs and G stage. (B) The association between pNENs and lymph node invasion. (C) The association between pNENs and vascular invasion. (D) The association between pNENs and metastasis.

TMN stage

TMN stage was mentioned in 4 articles[18,22,24,25]. On the basis of current knowledge, people with advanced TMN stage are more likely to have a negative outcome. However, only 1 article[18], along with combined data and subgroup analysis approved this standpoint. The rest articles showed no difference.

Lymph node

While 2 of 6 articles[19,23] showed no difference in people with or without lymph node invasion, 4 articles[17,20-22] reflected that people with lymph node invasion had worse prognosis than people without lymph node invasion. The combined data subordinate to the majority (Table 4, Fig. 3B). In the subgroup analysis, poor prognosis was associated with the people with lymph node invasion based on the articles with large samples and studies conducted in Asian or western countries.

Vascular invasion

2 articles[13,25] with more than 80 patients supported that vascular invasion involvement is related to a poor outcome. In contrast, 1 article[22] with small samples suggested that there is no difference in people with or without vascular invasion (Table 4, Fig. 3C).

Organ Metastasis

Present organ metastasis might indicate low overall survival of pNENs according to the data provided by 3 of 4 articles[13,20,27] and the combined data (Table 4, Fig. 3D). All subgroup analysis also showed the identical results.

Tumor size

5 studies[17,19,21,24,26] were mentioned in our study. 4[19,21,24,26] of them showed no correlation with the size of tumor and prognosis of pNENs.1 of them suggested that people with tumor in large size might have a poor prognosis.

Necrosis

Study[17] carried by Demir et al. showed that necrosis was a negative prognostic factor for pNENs. The other article[13] written by Xu Han et al. hold a conservative attitude.

Discussion

Pancreatic neuroendocrine tumors are rare and heterogeneous tumors with poorly defined natural history and uncertain biological behavior[28,29]. With advances in imaging techniques, pNETs are now being detected with increasing frequency in many regions of the world[30]. However, there is still no set of standard rules to determine the prognosis of patients. In this study, we reviewed several related prognostic factors for pNENs to further confirm their roles. As far as we know, we, for the first time, assessed the significance of prognostic factors above for pNENs in a meta-analysis. Based on the combined HR and 95% CI, we believe that negative prognostic factors consists of positive surgical resection margin and lymph node, advanced G stage and TMN stage, present organ metastasis, vascular invasion and the necrosis of specimens. Thus, patients with aforementioned factors should gain more attention and be examined more frequently during the follow-up. However, the only one positive prognostic factor is function. Therefore, patients with non-functional tumors should also show more concern on themselves. Furthermore, our study found that many other prognostic factors such as age, gender, surgical type and size of tumor do not play a decisive role in the process of pNENs. We might have a conservative view for these factors due to the lack of enrolled studies and the limited sample size. Therefore, more studies about some potential prognostic factors were greatly needed, especially studies with a large number of patients. To reduce the effect of small samples and regional disparity on heterogeneity, we performed the subgroup analysis based on sample size and nationality of patients. For almost all of subgroup analysis, we found that there is a small change in the value of combined 95% CI based on the large samples and patients in Asia or western countries, but the relationship between 95% CI and 1 hasn’t changed. Therefore, there is no decisive effect on heterogeneity in the studies based on small sample and geographic distance. For function, the nationality of patients was identified as main factor resulting in heterogeneity. Of course, many other factors could also result in the heterogeneity, such as year of articles. There are some limitations concerning this study. Firstly, some articles only provide Kaplan-Meier curve but not HR or follow-up data. During the process of computation, we may increase the deviation from the original data. In addition, many other factors might be responsible for the overall survival. However, due to the lack of sufficient articles or effective data, they were not assessed in our study. Moreover, the cutoff value to define high and low or positive and negative varies among some studies, which increased the difficulty with performing a pooled study. Last but not least, randomized controlled trials were in need to improve the reliability of reported data. In conclusion, this meta-analysis indicates that positive surgical resection margin and lymph node, advance G stage and TMN stage, present organ metastasis, vascular invasion and the necrosis of specimens might be associated with a poor prognosis of pNENs. These findings will provide important theoretical basis for improvement in clinical follow-up of patients with pNENs and may increase overall survival in a long term. However, due to the limitations mentioned above, further well-designed studies with larger sample size are required to confirm the predictive roles of those factors.

Materials and Methods

Literature search

Potential studies were selected by screening PubMed, EMBASE, Web of Science, Ovid, and The Cochrane Library dating up to September 2017. In Pubmed and Cochrane Library, the following keywords were applied in searching: (neuroendocrine tumors[Title/Abstract] OR neuroendocrine tumor[Title/Abstract] OR neuroendocrine neoplasms[Title/Abstract] OR neuroendocrine neoplasm[Title/Abstract]) AND (prognosis[Title/Abstract] OR prognostic factor[Title/Abstract]). In Web of Science and Ovid, we used the following search strings: (neuroendocrine tumors[Title]OR neuroendocrine tumor[Title] OR neuroendocrine neoplasms[Title] OR neuroendocrine neoplasm[Title]) AND (prognosis[Title] OR prognostic factor[Title]). In EMBASE, we searched for neuroendocrine neoplasms OR neuroendocrine neoplasm OR neuroendocrine tumor OR neuroendocrine tumors AND prognosis. The last search was performed on Sep 17, 2017. In addition, the search results were supplemented by examining references mentioned in the original articles.

Inclusion and exclusion criteria

Studies were included if they met the following criteria: pancreatic neuroendocrine tumor was histopathologically diagnosed. Relevant risk estimated in terms of hazard ratio with 95% confidence interval, or KM curve was provided. The following criteria were applied to exclude studies: no full text or available data non-English language conference abstract or review basic research or preclinical research.

Study quality assessment

The quality of included studies was assessed by two independent reviewers according to the Newcastle-Ottawa Quality Assessment Scale for cohort studies (NOS) recommended in the Cochrane Handbook version 5.1.0[31]. NOS is comprised of three parameters (eight elements, nine stars total) for quality: selection (four elements, one star each), comparability (one element, up to two stars) and outcome (three elements, one star each). The high-quality choices for each element are marked with a star, and then the number of stars is counted to evaluate the quality of each study. Studies are regarded as high quality if they are awarded six stars or more[32].

Data extraction

Two independent researchers carefully reviewed each eligible article and extracted the data. Any controversial data were resolved by a third researcher. For each enrolled study, the basic information extracted was shown: author name, year of publication, country, study types, study period and sample size. Potential prognostic factors mentioned in more than or equal to two articles were recorded. Gender, age, function, surgical type and margin, G and TMN stage, lymph node and vascular invasion, organ metastasis, tumor size and necrosis were finally selected. Subsequently, the number of articles, Hazard ratio, 95% confidence interval (CI) were acquired for each prognostic factor. If the data could not be obtained directly, we extracted survival rates from Kaplan-Meier survival curve, imported the data into Engauge Digitizer 4.1 to and calculated relative values with the method mentioned in article published by Jayne F Tierney et al.[33].

Statistical analysis

Review Manager software (version 5.3; Cochrane Collaboration, Oxford, United Kingdom) was applied to perform this meta-analysis and provide related graphics. Combined hazard ratio is presented as forest plots. Subgroup analysis was performed stratifying on the sample size (>80 vs. <80) and study area(Asian area vs. Western area). Cochran’s Q test and Higgins’ I-squared test were used to test heterogeneity between studies. Heterogeneity would not be considered significant if the P -value for Cochran’s Q test was greater than or equal to 0.1. In the absence of statistically significant heterogeneity, a fixed effects model was used to combine the data. Otherwise, a random effects model was applied. Supplementary Table
  32 in total

1.  Epidemiology, diagnosis, surgical treatment and prognosis of the pancreatic neuroendocrine tumors: Report of 125 patients from one single center.

Authors:  M Yang; B Tian; Y Zhang; A Su; P Yue; S Xu; L Wang
Journal:  Indian J Cancer       Date:  2015 Jul-Sep       Impact factor: 1.224

2.  Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.

Authors:  Joyce Wong; William J Fulp; Jonathan R Strosberg; Larry K Kvols; Barbara A Centeno; Pamela J Hodul
Journal:  Am J Surg       Date:  2014-06-08       Impact factor: 2.565

Review 3.  Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment.

Authors:  Alexander D J Baur; Marianne Pavel; Vikas Prasad; Timm Denecke
Journal:  Acta Radiol       Date:  2015-04-08       Impact factor: 1.990

4.  Significance of lymph node metastasis in pancreatic neuroendocrine tumor.

Authors:  Katsunobu Taki; Daisuke Hashimoto; Shigeki Nakagawa; Nobuyuki Ozaki; Shinjiro Tomiyasu; Masaki Ohmuraya; Kota Arima; Takayoshi Kaida; Takaaki Higashi; Keita Sakamoto; Kazuya Sakata; Hirohisa Okabe; Hidetoshi Nitta; Hiromitsu Hayashi; Akira Chikamoto; Toru Beppu; Hiroshi Takamori; Masahiko Hirota; Hideo Baba
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

Review 5.  Functioning and nonfunctioning neuroendocrine tumors of the pancreas.

Authors:  Elijah Dixon; Janice L Pasieka
Journal:  Curr Opin Oncol       Date:  2007-01       Impact factor: 3.645

6.  [Clinical characteristics and malignant predictive factors of pancreatic neuroendocrine tumors].

Authors:  Jeung Hye Han; Myung-Hwan Kim; Sung Hoon Moon; Soo Jung Park; Do Hyun Park; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee; Song Cheol Kim; Duck Jong Han
Journal:  Korean J Gastroenterol       Date:  2009-02

Review 7.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 8.  A short history of neuroendocrine tumours and their peptide hormones.

Authors:  Wouter W de Herder; Jens F Rehfeld; Mark Kidd; Irvin M Modlin
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-10-23       Impact factor: 4.690

Review 9.  Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis.

Authors:  Stephanie L M Das; Primal P Singh; Anthony R J Phillips; Rinki Murphy; John A Windsor; Maxim S Petrov
Journal:  Gut       Date:  2013-08-08       Impact factor: 23.059

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  9 in total

Review 1.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

2.  Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.

Authors:  V Andreasi; C Ricci; R Casadei; M Falconi; S Partelli; G Guarneri; C Ingaldi; F Muffatti; S Crippa
Journal:  J Endocrinol Invest       Date:  2021-11-13       Impact factor: 4.256

3.  Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database.

Authors:  Abuduhaibaier Sadula; Gang Li; Dianrong Xiu; Chen Ye; Siqian Ren; Xin Guo; Chunhui Yuan
Journal:  Comput Math Methods Med       Date:  2022-05-12       Impact factor: 2.809

4.  A New Preoperative Scoring System for Predicting Aggressiveness of Non-Functioning Pancreatic Neuroendocrine Neoplasms.

Authors:  Tetsuya Takikawa; Kazuhiro Kikuta; Shin Hamada; Kiyoshi Kume; Shin Miura; Naoki Yoshida; Yu Tanaka; Ryotaro Matsumoto; Mio Ikeda; Fumiya Kataoka; Akira Sasaki; Hidehiro Hayashi; Waku Hatta; Yohei Ogata; Kei Nakagawa; Michiaki Unno; Atsushi Masamune
Journal:  Diagnostics (Basel)       Date:  2022-02-03

5.  Predictive value of the Ki67 index for lymph node metastasis of small non-functioning pancreatic neuroendocrine neoplasms.

Authors:  Toshihiko Masui; Asahi Sato; Kenzo Nakano; Yuichiro Uchida; Akitada Yogo; Takayuki Anazawa; Kazuyuki Nagai; Yoshiya Kawaguchi; Kyoichi Takaori; Shinji Uemoto
Journal:  Surg Today       Date:  2019-03-05       Impact factor: 2.549

6.  PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker.

Authors:  Timothy M Horton; Vandana Sundaram; Christine Hye-Jin Lee; Kathleen Hornbacker; Aidan Van Vleck; Kaisha N Benjamin; Allison Zemek; Teri A Longacre; Pamela L Kunz; Justin P Annes
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

7.  Transcriptional Profiling Reveals the Regulatory Role of DNER in Promoting Pancreatic Neuroendocrine Neoplasms.

Authors:  Rui He; Wunai Zhang; Shuo Chen; Yang Liu; Wenbin Yang; Junhui Li
Journal:  Front Genet       Date:  2020-11-27       Impact factor: 4.599

Review 8.  Circulating Angiogenic Markers in Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review.

Authors:  Irina Sandra; Irina Mihaela Cazacu; Vlad Mihai Croitoru; Mariana Mihaila; Vlad Herlea; Mircea Mihai Diculescu; Simona Olimpia Dima; Adina Emilia Croitoru
Journal:  Curr Issues Mol Biol       Date:  2022-09-04       Impact factor: 2.976

9.  Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score-Based Inverse Probability of Treatment Weighting.

Authors:  Jingyuan Ye; Hongyu Wu; Jinzheng Li; Changan Liu
Journal:  Front Surg       Date:  2022-07-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.